Innovent Biologics (HKSE:01801) FCF Yield % : -2.11 (As of May. 14, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Innovent Biologics's Trailing 12-Month Free Cash Flow is HK$-1,352 Mil, and Market Cap is HK$63,981 Mil. Therefore, Innovent Biologics's FCF Yield % for today is -2.11%.

The historical rank and industry rank for Innovent Biologics's FCF Yield % or its related term are showing as below:

HKSE:01801' s FCF Yield % Range Over the Past 10 Years
Min: -23.05 Med: -6.13 Max: -0.95
Current: -2.11

During the past 8 years, the highest FCF Yield % of Innovent Biologics was -0.95%. The lowest was -23.05%. And the median was -6.13%.

HKSE:01801's FCF Yield % is ranked better than
79.02% of 1554 companies
in the Biotechnology industry
Industry Median: -14.38 vs HKSE:01801: -2.11

Innovent Biologics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.39%.

Innovent Biologics FCF Yield % Historical Data

The historical data trend for Innovent Biologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics FCF Yield % Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-6.74

-1.10

-6.72

-7.17

-1.95

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial										-8.49	-5.88	-8.76	-5.99	0.04

Competitive Comparison of Innovent Biologics's FCF Yield %

For the Biotechnology subindustry, Innovent Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's FCF Yield % falls into.

Innovent Biologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Innovent Biologics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1351.528	/	69333.2325
	=	-1.95%

Innovent Biologics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	14.926	*	2	/	69333.2325
	=	0.04%

Innovent Biologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Innovent Biologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines